KR102482710B1 - 항-pd-1 항체, 이의 생산 방법 및 사용 방법 - Google Patents

항-pd-1 항체, 이의 생산 방법 및 사용 방법 Download PDF

Info

Publication number
KR102482710B1
KR102482710B1 KR1020197003862A KR20197003862A KR102482710B1 KR 102482710 B1 KR102482710 B1 KR 102482710B1 KR 1020197003862 A KR1020197003862 A KR 1020197003862A KR 20197003862 A KR20197003862 A KR 20197003862A KR 102482710 B1 KR102482710 B1 KR 102482710B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding
antibodies
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197003862A
Other languages
English (en)
Korean (ko)
Other versions
KR20190029641A (ko
Inventor
빅토리아 미카일로브나 에키모바
드미트리 발레리에비치 코르자빈
율리아 세르게브나 체르니흐
티모페이 알렉산드로비치 네만킨
발레리 블라디미로비치 솔로브예프
안나 콘스탄티노브나 블라디미로바
이리나 안드레브나 블란키나
세르게이 바실리에비치 디두크
올가 블라디미로브나 곤차로바
안나 블라디미로브나 에로쇼바
이아코프 이우레비치 우스티우고프
마리나 블라디미로브나 아르티우코바
안드레이 보리소비치 울리틴
로만 알렉세예비치 이바노프
드미트리 발렌티노비치 모르조프
Original Assignee
조인트 스탁 컴퍼니 “바이오케드”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조인트 스탁 컴퍼니 “바이오케드” filed Critical 조인트 스탁 컴퍼니 “바이오케드”
Publication of KR20190029641A publication Critical patent/KR20190029641A/ko
Application granted granted Critical
Publication of KR102482710B1 publication Critical patent/KR102482710B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197003862A 2016-07-13 2017-07-04 항-pd-1 항체, 이의 생산 방법 및 사용 방법 Active KR102482710B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения
RU2016128487 2016-07-13
PCT/RU2017/050056 WO2018013017A1 (ru) 2016-07-13 2017-07-04 Анти-pd-1-антитела, способ их получения и способ применения

Publications (2)

Publication Number Publication Date
KR20190029641A KR20190029641A (ko) 2019-03-20
KR102482710B1 true KR102482710B1 (ko) 2023-01-02

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003862A Active KR102482710B1 (ko) 2016-07-13 2017-07-04 항-pd-1 항체, 이의 생산 방법 및 사용 방법

Country Status (21)

Country Link
US (1) US11136408B2 (enExample)
EP (1) EP3486257A4 (enExample)
JP (1) JP6993992B2 (enExample)
KR (1) KR102482710B1 (enExample)
CN (1) CN110023335B (enExample)
BR (1) BR112019000436A2 (enExample)
CA (1) CA3021372A1 (enExample)
CL (1) CL2018003407A1 (enExample)
CO (1) CO2019001246A2 (enExample)
CR (1) CR20190009A (enExample)
EC (1) ECSP19010852A (enExample)
JO (1) JOP20190002A1 (enExample)
MA (1) MA44547B1 (enExample)
MX (1) MX2018014937A (enExample)
NI (1) NI201900002A (enExample)
NZ (1) NZ750221A (enExample)
PE (1) PE20190450A1 (enExample)
PH (1) PH12018550179A1 (enExample)
RU (1) RU2656181C1 (enExample)
WO (1) WO2018013017A1 (enExample)
ZA (1) ZA201900792B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
CN117586401A (zh) 2017-01-20 2024-02-23 大有华夏生物医药集团有限公司 抗pd-1抗体及其用途
IL269970B (en) 2017-04-14 2022-09-01 Tallac Therapeutics Inc Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
KR102692379B1 (ko) 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN112424231B (zh) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
KR20230163503A (ko) * 2021-03-31 2023-11-30 메뤼스 엔.페. 신규한 pd-1 결합 도메인
BR112023020856A2 (pt) 2021-04-08 2024-02-06 Biocad Joint Stock Co Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521768A (ja) 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
US20160068586A1 (en) 2010-03-11 2016-03-10 Ucb Biopharma Sprl Pd-1 antibodies
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2535354B1 (en) * 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN104961829B (zh) * 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
HUE041335T2 (hu) * 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
PT2992017T (pt) * 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
RS63571B9 (sr) * 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
ES2819451T3 (es) * 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521768A (ja) 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
US20160068586A1 (en) 2010-03-11 2016-03-10 Ucb Biopharma Sprl Pd-1 antibodies
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies

Also Published As

Publication number Publication date
PE20190450A1 (es) 2019-03-29
JP2019527543A (ja) 2019-10-03
CL2018003407A1 (es) 2019-03-29
PH12018550179A1 (en) 2019-03-11
JOP20190002A1 (ar) 2019-01-10
CR20190009A (es) 2019-06-05
US20190127478A1 (en) 2019-05-02
CO2019001246A2 (es) 2019-02-19
MA44547A1 (fr) 2020-01-31
EP3486257A1 (en) 2019-05-22
MX2018014937A (es) 2019-05-16
CN110023335B (zh) 2024-05-17
EP3486257A4 (en) 2020-03-04
NZ750221A (en) 2022-09-30
ECSP19010852A (es) 2019-06-30
NI201900002A (es) 2019-06-11
CN110023335A (zh) 2019-07-16
RU2656181C1 (ru) 2018-05-31
MA44547B1 (fr) 2021-09-30
AU2017297138A2 (en) 2019-02-21
JP6993992B2 (ja) 2022-01-14
US11136408B2 (en) 2021-10-05
WO2018013017A1 (ru) 2018-01-18
ZA201900792B (en) 2020-03-25
KR20190029641A (ko) 2019-03-20
BR112019000436A2 (pt) 2019-10-01
AU2017297138A1 (en) 2019-02-14
AU2017297138A8 (en) 2019-02-28
CA3021372A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
KR102482710B1 (ko) 항-pd-1 항체, 이의 생산 방법 및 사용 방법
JP7488323B2 (ja) 抗ｌａｇ－３抗体および組成物
TWI751981B (zh) 抗pd-1抗體及組成物
KR20190099223A (ko) 암 치료용 결합 분자
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
KR20170054517A (ko) 항-ｍｅｔ 항체 및 조성물
US20230235090A1 (en) Bispecific antibody and use thereof
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
US20220411513A1 (en) Anti-pd-l1 antigen binding protein and application thereof
JP2025038001A (ja) Ｐｄｇｆ－ｂおよびｐｄｇｆ－ｄに結合する抗原結合分子ならびにその使用
KR102602564B1 (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
CN116041513A (zh) 靶向rankl的治疗性抗体
CN118804927A (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
JP6529602B2 (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
US20230295310A1 (en) CD3 T-Cell Engagers and Methods of Use
US20250277038A1 (en) Anti-pd-l1 antibody and use thereof
HK40003751A (en) Anti-pd-1 antibodies, method for producing same and method for using same
OA19651A (en) Anti-Pd-1 antibodies, method for producing same and method for using same.
HK40003751B (zh) 抗-pd-1 抗体、其生产方法及其使用方法
HK40103769A (en) Fcrn antibodies and methods of use thereof
NZ793343A (en) Anti- LAG-3 antibodies and compositions
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4